Tous Actualités
Suivre
Abonner Roche Pharmaceuticals

Roche Pharmaceuticals

Anticipated Approval of Latest HIV Drug Will Give Treatment-Experienced Patients the Best Chance Yet to Achieve Undetectable Viral Load

Basel, Switzerland (ots/PRNewswire)

- Newest HIV Drug Works Better in Combination With FUZEON(R)
The emergence of new HIV treatments, such as boosted protease
inhibitors (PI), has led to a change in treatment goals for people
living with drug-resistant HIV. Up until recently, it has been
reluctantly considered acceptable for treatment-experienced patients
to continue to have a detectable viral load (more than 50 copies of
viral RNA per ml of blood) so long as their immune system can be
preserved. The consequences of remaining detectable are that patients
are likely to accumulate drug resistance, with a consequent loss of
future antiretroviral treatment options, and ultimately leading to a
decrease in immune function and clinical disease progression.
However, guidelines issued by the US Department of Health and Human
Services (DHHS) recommend establishing maximal viral suppression in
this patient population and support the use of FUZEON with an active
boosted PI to achieve this objective.
The anticipated upcoming US approval of Tibotec's boosted PI
darunavir (TMC114/r) is good news for treatment-experienced patients
facing drug resistance. It means that they will soon be able to
benefit from potentially two active agents which, when used together,
can substantially increase their chances of reaching undetectable
viral load.

Contact:

For more information, please contact: Alexander Watson, Ketchum,
Office: +44-207-611-3663, E-Mail: alexander.watson@ketchum.com

Plus de actualités: Roche Pharmaceuticals
Plus de actualités: Roche Pharmaceuticals